Table 2.
Characteristics of included clinical trial populations
| Clinical trial | Duration (weeks) | Diagnostic groups (number in full analysis set) | Treatment groups | na | Dropouts (%) | Age, years, mean (SD) | Sex, % female | Body weight, kg, mean (SD) | Prior intake of antidementia drugs (n) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||||
| AD | VaD | Mixed | |||||||||
| Kanowski et al33,34 | 24 | 158 | 47 | – | EGb 240 mg | 109 | 16 (14.7) | 72 (10) | 68 | 69 (13) | Nonec |
| Placebo | 107 | 16 (15.0) | 72 (10) | 71 | 67 (13) | Nonec | |||||
| Le Bars et al30,31 | 52b | 236 | 73 | – | EGb 120 mg | 161 | 39 (24.2) | 69 (10) | 51 | 69 (14) | Nonec |
| Placebo | 166 | 44 (26.5) | 69 (10) | 56 | 70 (13) | Nonec | |||||
| Schneider et al32 | 26 | 513 | – | – | EGb 240 mg | 170 | 30 (18) | 78 (7) | 56 | 68 (14) | NDd |
| EGb 120 mg | 169 | 34 (20) | 79 (7) | 50 | 6 (15) | NDd | |||||
| Placebo | 174 | 39 (22) | 78 (7) | 52 | 70 (13) | NDd | |||||
| Nikolova et al14 | 22 | 178 | 80 | 139 | EGb 240 mg | 203 | 13 (6) | 69 (8) | 57 | 72 (13) | 4 |
| Placebo | 205 | 17 (8) | 69 (8) | 60 | 72 (14) | 3 | |||||
| Napryeyenko et al35 | 22 | 53 | 181 | 161 | EGb 240 mg | 200 | 4 (2) | 65 (8) | 86 | 74 (12) | 2 |
| Placebo | 200 | 5 (3) | 63 (8) | 82 | 73 (11) | 0 | |||||
| Ihl et al36 | 24 | 121 | 71 | 212 | EGb 240 mg | 206 | 16 (8) | 65 (10) | 69 | 74 (14) | 0 |
| Placebo | 204 | 12 (6) | 65 (9) | 66 | 74 (14) | 0 | |||||
| Herrschaft et al13 | 24 | 208 | 42 | 152 | EGb 240 mg | 205 | 7 (3) | 65 (9) | 70 | 76 (13) | 1 |
| Placebo | 205 | 5 (2) | 65 (9) | 69 | 73 (13) | 4 | |||||
Notes: –There were no patients with these diagnoses.
*
AD with cerebrovascular disease.
a
n includes all patients randomized;
b
data for week 26 analyzed and presented;
c
there were no approved antidementia drugs when these trials were conducted;
d
not determinable (ND).
Many patients had participated in double-blind, controlled clinical trials of antidementia drugs before. How many patients received an effective antidementia drug, placebo, or an ineffective investigational drug within these trials is not known.
Abbreviations: EGb, EGb 761®; AD, Alzheimer’s disease; VaD, vascular dementia; SD, standard deviation.